glp-1/gip/gcg receptor agonist The activity of GLP-1 and GIP for Type 2 Diabetes and Obesity LY3437943, a novel triple glucagon,

Evaluating what the research shows about GLP-1 medications and depression and suicidal ideation.

It is a monosaccharide, which means it is a single sugar molecule

other outcomes were cardiovascular and total death, nonfatal myocardial infarction (MI), nonfatal stroke, hospitalization for heart failure (HHF), and renal outcome

In both mice and humans, glucagon administration enhances energy expenditure and suppresses food ...

Neurodegenerative diseases, including Alzheimers Disease (AD) and Parkinsons Disease (PD) are common complications of diabetes, arising from insulin resistance, inflammation, and other pathological processes in the central nervous system

The World Obesity Atlas 2024 reports over 1.5 billion projected cases by 2035, highlighting its growing threat among pediatric and adult populations globally